Understand the source comparison
Best Peptides for Brain Injury Recovery: Research Comparison
Cerebrolysin BDNF/NGF mimetic. Neurotrophic receptor activation Human RCTs in TBI populations Intravenous infusion 12% improvement in favorable outcomes (GOS 4–5) at 6 months in pooled analysis of 2,117 patients Approved for TBI in 40+ countries; not FDA-appro
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- BDNF/NGF mimetic. Neurotrophic receptor activation
- Human RCTs in TBI populations
- Intravenous infusion
- 12% improvement in favorable outcomes (GOS 4–5) at 6 months in pooled analysis of 2,117 patients
- Approved for TBI in 40+ countries; not FDA-approved in US
- P21
- CNTF derivative. JAK-STAT pathway activation, hippocampal neurogenesis
- Robust animal TBI models, no human trials
- Intranasal administration
- 240% increase in hippocampal neurogenesis, spatial memory restoration in rodent concussion models
- Preclinical only; requires IND approval for human studies
- Dihexa
- HGF/c-Met pathway modulator. Synaptic density enhancement
- Animal TBI models, extended therapeutic window
- Oral (bioavailable peptide)
- 85% restoration of dendritic spine density within 3 weeks; effective even when administered 3 months post-injury
- Phase I human safety trials in non-TBI populations; no TBI-specific human data
- Semax
- ACTH analog. Dopaminergic and noradrenergic modulation
- Healthy-subject cognitive studies, limited TBI research
- Improved attention and working memory in non-injured adults; single-lab TBI reports without replication
- Nootropic evidence only; TBI application underexplored